Moderna, Inc.: Phase 1/2 Interim Data on Moderna's mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia , Presented at the 2023 ASGCT Annual Meeting

First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacementTo date, mRNA-3927 has been generally well-tolerated at the doses administered, with encouraging early

Related Keywords

United States ,Cambridge ,Cambridgeshire ,United Kingdom ,American ,Mary Beth Woodin ,Lavina Talukdar ,Kyle Holen ,Gewinn Nur ,Exchange Commission ,Head Of Development ,Moderna Inc ,American Society Of Gene ,Wrd Communications ,Moderna Inc View ,Nasdaq ,Cell Therapy ,Senior Vice President ,Propionic Acidemia ,Great Place ,Private Securities Litigation Reform Act ,Annual Report ,Vice President ,Inc View ,Moderna ,Hase ,Interim ,Data ,Rna ,1927 ,Investigational ,Therapy ,Propionic ,Acidemia ,Resented ,023 ,Sgct ,Nnual ,Meeting ,